Latest AbbVie News & Updates

See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.

AbbVie

Biopharmaceutical company

abbvie.com

Headquarters: North Chicago, United States
Company type: Public company
Number of employees: 60,000+

Last updated Today

Latest news about AbbVie

In short: AbbVie reported strong first-quarter 2026 results and raised its full-year guidance, driven by growth in its immunology and neuroscience portfolios.

Company announcements

June 12 AbbVie

AbbVie presents new nine-year data for venetoclax in first-line CLL

Final results from Phase 3 CLL14 trial show superior progression-free survival and median time to next treatment of 7.6 years.

June 8 AbbVie

AbbVie presents new blood cancer data at EHA 2026

Data includes 21 oral and poster presentations on epcoritamab, venetoclax, etentamig, and pivekimab sunirine across multiple hematologic cancers.

June 2 AbbVie

AbbVie announces EC approval of AQUIPTA

The EC approved atogepant for acute and preventive migraine treatment in adults, based on Phase 3 ECLIPSE data showing two-hour pain freedom and sustained relief up to 48 hours.

May 29 AbbVie

AbbVie announces expanded EU label for VENCLYXTO in CLL

The European Commission authorized VENCLYXTO with acalabrutinib or ibrutinib for previously untreated CLL, supported by Phase 3 trials.

Media coverage

Yesterday Bloomberg Law

HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

The US Department of Health and Human Services is asking a federal court to throw out a case from AbbVie Inc. that challenges its interpretation...

Yesterday TipRanks

AbbVie’s New Phase 3 Colorectal Cancer Trial Puts ABBV-400 in the Late-Stage Spotlight - TipRanks.com

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is running a late-stage cancer study called “An Open-Label, Randomized, Controlled, Globa...

Yesterday Yahoo Finance

AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress

AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated...

June 16 Yahoo Finance

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just...

Never miss news about AbbVie

Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AbbVie competitors & trending companies

Browse news for competitors to AbbVie and other trending companies.